Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

NCT05059522 · tracked via the Priya Life Science UK tracker

Sponsor

Pfizer

Phase

Phase 3

Started

2021-09-29

Last updated

2026-06-22

Condition(s) studied

Advanced MalignanciesNSCLCOvarian CancerUrothelial CancerSolid Tumors

Investigational drug(s) / intervention(s)

AvelumabLorlatanibTalazoparibPemetrexedAxitinibCMP 001UtomilumabPF04518600

Avelumab: oral

Lorlatanib: oral

Talazoparib: oral

Pemetrexed: IV (intravenous) infusion

Axitinib: oral

CMP 001: IT (intratumoral) or SC (subcutaneous)

Utomilumab: IV infusion

PF04518600: IV infusion

Study summary

This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Any participant who is receiving study treatment and deriving significant clinical benefit or is in the safety and/or survival follow-up period in a Pfizer-sponsored Avelumab Parent Study. 2. Participants must agree to follow the reproductive criteria. 3. Participants must be willing and able to comply with all scheduled visits, treatment plan, and other study procedures. Exclusion Criteria: 1. Female participants who are pregnant or breastfeeding. 2. Any medical reason that, in the opinion of the Investigator or Sponsor, precludes the participant from inclusion in the study.

Primary outcome measure(s)

Number of participants with adverse events leading to permanent discontinuation of study intervention — Baseline up to approximately 5 years
Number serious adverse events reported for all participants — Baseline up to approximately 5 years

Trial sites (71)

Facility	City	Region
Highlands Oncology Group, PA	Fayetteville	Arkansas
Highlands Oncology Group, PA	Rogers	Arkansas
Highlands Oncology Group, PA	Springdale	Arkansas
The Regents of the University of California	Los Angeles	California
UCLA Hematology/Oncology	Los Angeles	California
Moffitt Cancer Center	Tampa	Florida
MSK Basking Ridge	Basking Ridge	New Jersey
MSK Monmouth	Middletown	New Jersey
MSK Bergen	Montvale	New Jersey
MSK Commack	Commack	New York
MSK Westchester	Harrison	New York
Memorial Sloan Kettering Cancer Center (IDS Pharmacy)	Long Island City	New York
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).	New York	New York
Memorial Sloan Kettering Cancer Center 53rd street.	New York	New York
Memorial Sloan Kettering Cancer Center	New York	New York
MSK Nassau	Uniondale	New York
Hospital of the University of Pennsylvania	Philadelphia	Pennsylvania
The Trustees of the University of Pennsylvania, Clinical Research (OCR)	Philadelphia	Pennsylvania
The University of Texas MD Anderson Cancer Center	Houston	Texas
Fred Hutchinson Cancer Center	Seattle	Washington
Macquarie University	North Ryde	New South Wales
Mater Hospital Sydney	Wollstonecraft	New South Wales
Melanoma Institute Australia	Wollstonecraft	New South Wales
The Prince Charles Hospital	Chermside	Queensland
UZ Gent	Ghent	Oost-vlaanderen
Grand Hôpital de Charleroi	Gilly	Belgium
Cross Cancer Institute	Edmonton	Alberta
Kingston Health Sciences Centre-Kingston General Hospital Site	Kingston	Ontario
Aalborg Universitetshospital, Syd	Aalborg	North Denmark
Institut de Cancérologie de Lorraine Alexis Vautrin	Vandœuvre-lès-Nancy	Lorraine
Országos Onkológiai Intézet	Budapest	Hungary
Rabin Medical Center	Petah Tikva	Central District
Fondazione IRCCS Istituto Nazionale dei Tumori	Milan	Lombardy
Fondazione IRCCS Istituto Nazionale dei Tumori	Milan	Milano
IRCCS Istituto Clinico Humanitas	Rozzano	Milano
Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi	Ancona	Italy
Oita University Hospital	Yufu	Oita Prefecture
National Cancer Center Hospital	Chuo-ku	Tokyo
Japanese Foundation for Cancer Research	Koto	Tokyo
National Hospital Organization Kyushu Cancer Center	Fukuoka	Japan

+ 31 more sites — see the full list on the official registry below.

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05059522 on ClinicalTrials.gov ↗ ← All trials in the UK